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Abstract
Background:  Genomic, transcriptomic and proteomic projects often suffer from a lack of
functional validation creating a strong demand for specific and versatile antibodies. Antibody phage
display represents an attractive approach to select rapidly in vitro the equivalent of monoclonal
antibodies, like single chain Fv antibodies, in an inexpensive and animal free way. However, so far,
recombinant antibodies have not managed to impose themselves as efficient alternatives to natural
antibodies.
Results: We developed a series of vectors that allow one to easily fuse single chain Fv antibodies
to Fc domains of immunoglobulins, improving their sensitivity and facilitating their use. This series
enables the fusion of single chain Fv antibodies with human, mouse or rabbit Fc so that a given
antibody is no longer restricted to a particular species. This opens up unlimited multiplexing
possibilities and gives additional value to recombinant antibodies. We also show that this multi-Fc
species production system can be applied to natural monoclonal antibodies cloned as single chain
Fv antibodies and we converted the widely used 9E10 mouse anti-Myc-tag antibody into a human
and a rabbit antibody.
Conclusion: Altogether, this new expression system, that brings constant quality, sensitivity and
unique versatility, will be important to broaden the use of recombinant and natural monoclonal
antibodies both for laboratory and diagnosis use.
Background
Antibodies are essential tools for the identification and
study of proteins involved in normal and pathological
functions. Our need for specific antibodies will further
increase in the post-genomic era [1]. Recombinant anti-
bodies like single chain Fv (scFv) represent an attractive
alternative to natural antibodies. In particular, they can be
selected using synthetic in vitro approaches like phage or
ribosome display allowing fast, specific, animal-experi-
ment independent and rather inexpensive selection of
antibody [2]. These antibodies can then be used, in prin-
ciple, in any approach where natural antibodies are usu-
ally employed.
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Nevertheless, this method of antibody generation has not
imposed itself within academic use and almost no such
recombinant antibodies are distributed commercially as
laboratory or diagnosis reagents. This is rather surprising
as currently available libraries are of large enough diver-
sity to provide a high success rate with a very low techno-
logical investment. Some large scale approaches are
currently developed partly based on recombinant anti-
bodies [[3,4]; see also http://www.antibody-factory.de]
and we and others even showed that this approach allows
the selection of antibodies that would be hard/impossible
to obtain by other means [see for example [5-7]]. One of
the main reasons for this lack of popularity is probably the
general feeling that the sensitivity of recombinant anti-
bodies is lower than that of natural antibodies. The appar-
ent reduced affinity is mostly due to the fact that scFv are
monovalent molecules that lack the avidity binding
obtained through dimerization. Another limitation is that
the end product is not exactly an antibody, but only an
antibody fragment, which is more complicated to use
than its natural counterpart.
To solve these limitations, we developed a series of expres-
sion vectors based on the pFuse expression system (com-
mercially available from InvivoGen, see materials and
methods) that allow expression of scFv in fusion with nat-
ural Fc regions. This approach strongly improved anti-
body sensitivity and ease of use, and additionally
provided so far unavailable versatility since scFv can be
fused to human, mouse and rabbit Fc in an easy one step
cloning procedure. We further showed that this method
can be applied to natural antibodies re-cloned as scFv.
Thus, we fused the monoclonal anti-Myc antibody 9E10
to human and rabbit Fc and showed that, as for recom-
binant antibodies, it provides extended multiplexing pos-
sibilities. We believe that the described method will be
decisive in allowing the recombinant antibody approach
to impose itself as a robust and powerful alternative
option for antibody isolation and usage.
Results
Plasmids construction and antibody production
Our plasmids are based on the pFUSE-Fc2(IL2ss)™ series
from Invivogen (San Diego, USA) that contains the inter-
leukin-2 (IL2) signal sequence and allows the secretion of
Fc-Fusion proteins by mammalian cells. They are selecta-
ble using Zeocin™ (Zeo) both in prokaryotic and eukaryo-
tic cells. These plasmids were modified by site directed
mutagenesis and adaptor insertion (see Material and
Methods, Figure 1A) to allow the easy one step cassette
cloning of recombinant antibodies extracted from a large
collection of common recombinant antibody selection
and expression plasmids (e.g pHEN, pSEX, pHAL,
pCANTAB, pHOG, pOPE, pSTE). Three plasmids were
constructed enabling fusion of scFv at their C-terminus
with either human IgG2 (h), mouse IgG2a (m) or the rab-
bit IgG (r) Fc domain (Fc regions comprise the CH2 and
CH3 domains of the IgG heavy chain and the hinge
region).
We sub-cloned the F2C antibody directed against alpha-
Tubulin [8] in fusion with the human, mouse or rabbit Fc
domains generating antibodies hF2C, mF2C and rF2C,
respectively. Three days after transient transfection of
CHO cells with these expression plasmids, secreted anti-
bodies were purified from cell supernatants using pro-
teinA-affarose and loaded on SDS-PAGE. Western blotting
analysis showed that each CHO supernatant expressed the
expected 53 kDa antibody that can be specifically detected
using anti-IgG antibodies directed against the respective
species (Figure 1B). Because the scFvs were fused to the
hinge domain of IgGs, the Fc domains were expected to
form di-sulfide bridges. We confirmed using SDS-PAGE
analysis that, in non-reducing conditions, the scFv-Fc
behave as dimeric proteins while they migrate as mono-
mers upon reduction (Figure 1C).
scFv versus scFv-hFc as tools for western blotting and 
immunofluorescence
We tested whether scFv-Fc could be efficiently used in
western blotting experiments. NP40 solubilised lysates of
HeLa cells were separated by SDS-PAGE and transferred to
nitrocellulose membrane. The membrane was cut and
incubated with either F2C or SF9 (directed against non-
muscle MyosinIIA [8]) fused to either human, mouse or
rabbit Fc domains. The membrane strips were then incu-
bated with species-specific HRP-labeled secondary anti-
bodies and subsequently developed. As shown in Figure
1D, we found that a specific band was detected in each
condition indicating that direct dilution of unpurified cul-
ture medium from transfected CHO cells transiently
expressing scFv-xFc (where x means human, rabbit or
mouse) can be used for western blot experiments.
We then assessed the Fc-fused scFvs for detection of anti-
gens by immunofluorescence. After fixation and permea-
bilization, HeLa cells were incubated with 4 different scFv
or with their 4 scFv-hFc counterparts (Figure 2). For each
antibody, the detection was at least as good and in general
better after Fc fusion, and its usability improved. For
example, while the anti-Rab6-GTP scFv scAA2 only gave
good labeling when used in conjunction with very short
washes [9], human hAA2 produced contrasted labeling
using classical immunofluorescence protocols. Similarly,
while the scFv TA10 can only detect Giantin when cells are
fixed in methanol, the fusion antibody hTA10 can detect
Giantin even when cells are fixed by paraformaldehyde
(unpublished results). More generally, we systematically
saw an increase in the sensitivity of scFv-Fc fusions com-
pared to simple scFvs.BMC Biotechnology 2009, 9:14 http://www.biomedcentral.com/1472-6750/9/14
Page 3 of 9
(page number not for citation purposes)
Production and use of multi-species scFv-Fc antibodies Figure 1
Production and use of multi-species scFv-Fc antibodies. A: Schematic map of the generic pFuse-xIgG-Fc2 used to 
express scFvs (adapted from Invivogen). Three vectors are available bearing either a human (pFuse-hIgG-Fc2), mouse (pFuse-
mIgG-Fc2) or rabbit IgG2 (pFuse-rIgG-Fc2). The scFv is inserted (NcoI/NotI) inframe between the IL2 secretion signal and the 
Fc portion. The vector can be selected using Zeocin both in E. coli and in mammalian cells. B: Western Blot analysis of the scFv 
F2C fused to Fc domains from 3 different species. hF2C, rF2C and mF2C secreted by CHO cells were purified on protein A 
and analyzed by western blot using either species-specific anti-Fc antibody, or using a polyclonal anti-scFv. Each F2C fusion anti-
body is detected in CHO supernatants and is respectively seen as a human, rabbit or mouse antibody.C: scFv-hFc are 
expressed as dimers. hF2C proteins were separated by SDS-PAGE either in reducing (left) or in non-reducing conditions 
(right) and analyzed by western blot. This confirmed that hF2C behaves as a dimer in non-reducing conditions. D: Using multi-
species scFv-Fc antibodies for Western blot immuno-labeling. A HeLa cell protein lysate was separated by SDS-PAGE and 
transferred on a nitrocellulose membrane. The membrane was probed using anti-MyosinII SF9 (lane 1, 3 and 5) or anti-Tubulin 
F2C (2, 4, 6) antibodies fused to either human (h; 1,2), rabbit (r; 3,4) or mouse (m; 5,6) Fc. This experiment shows that each 
scFv kept its specificity when used as a human, mouse or rabbit antibody.BMC Biotechnology 2009, 9:14 http://www.biomedcentral.com/1472-6750/9/14
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Using scFv-Fc antibody for immunofluorescence Figure 2
Using scFv-Fc antibody for immunofluorescence. Cells were immuno-labeled using either scFv (a, c, e, g) or scFv-hFc (b, 
d f, h) antibodies. scFv were detected using an anti-Myc tag antibody followed by Cy3-labeled anti-mouse antibodies and scFv-
hFc using Cy3-labeled anti-human antibodies (red). Nuclei were stained using DAPI (blue). AA2 (a, b), TA10 (c, d), SF9 (e, f) 
and F2C (g, h) detect respectively Rab6-GTP, Giantin, alpha-Tubulin and nonmuscle MyosinIIA. scFv fused to a hFc portion 
keep their specificity and are, in general, more sensitive and easier to use than their monomeric scFv counterparts. Bar = 20 
μm.BMC Biotechnology 2009, 9:14 http://www.biomedcentral.com/1472-6750/9/14
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Multi-species antibodies
By fusing scFv to Fc domains, not only are we endowing
recombinant antibodies with the same power as natural
antibodies for classical immunological methods, but we
also generate new and unique tools. Natural antibodies
are derived from a single host and thus linked to one spe-
cies definitively, which complicates multiplexing in many
cases. Here, since we developed a series of vectors that
allow not only fusion of scFv to human Fc but also to
mouse or rabbit IgGs in a single sub-cloning step (see Fig-
ure 1), there no longer exists a species barrier in co-immu-
nolabeling applications. AA2, F2C, SF9 and TA10 were
introduced in the 3 versions of the pFUSE-Fc modified
plasmids and, after transient transfection in CHO cells,
scFv-xFc fusion antibodies were recovered in supernatants
and used for immunofluorescence assay on HeLa cells
(Figure 3). We observed that human, rabbit or mouse ver-
sions of each scFv-Fc detected their respective target pro-
teins with similar efficiency (Figure 3A). This thus allows
one to carry out multicolor immunofluorescence labeling
using any combination of recombinant antibodies (Figure
3B) or of recombinant and natural antibodies (unpub-
lished data).
Finally, we showed that multi-species antibody technol-
ogy can also be adapted to natural antibodies, widening
their use. The 9E10 scFv (directed against the widely used
Myc tag) has been isolated from Myc1-9E10 hybridoma
cells before [10]. We sub-cloned it into our 3 versions of
pFUSE-Fc and produced h9E10, r9E10 and m9E10 in
CHO cells. The resulting multispecies 9E10 were then
tested by immunofluorescence using HeLa cells tran-
Immunofluorescence using multi-species antibodies Figure 3
Immunofluorescence using multi-species antibodies. A: The scFv-Fc F2C (a-c), SF9 (d-f), TA10 (g-i) and AA2 (j-l) in 
their human (a, d, g, j), mouse (b, e, h, k) or rabbit (c, f, i, l) versions can be used in immunofluorescence to detect their respec-
tive target proteins with similar efficiency (red). Bar = 20 μm. B: Using the multi-species approach, antibodies can be produced 
fused to any of the three IgG species. This allows a large diversity of multiplexing. In this example, Myosin, Tubulin and Giantin 
were co-detected in HeLa cells using the human version of SF9 (a), the mouse version of F2C (b) and the rabbit version of 
TA10 (c) respectively. The three labelings are shown overlayed in (d). Bar = 20 μm.BMC Biotechnology 2009, 9:14 http://www.biomedcentral.com/1472-6750/9/14
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Immunofluorescence using natural or multi-species anti-Myc 9E10 antibodies Figure 4
Immunofluorescence using natural or multi-species anti-Myc 9E10 antibodies. Hela cells expressing Myc- and GFP-
tagged CLIP-170 were immuno-labeled using either the natural mouse monoclonal antibody Myc1-9E10 (a-c) or the recom-
binant human (d-f), rabbit (g-i) or mouse (j-l) versions of 9E10 scFv fused to Fc domains. 9E10 antibodies were detected using 
Cy3-labeled secondary antibodies. GFP fluorescence was directly imaged in the green channel (green, a, d, g, h). The overlays 
(c, f, u, j) show the GFP fluorescence in green and 9E10 detection of Myc-tagged proteins in red. Nuclei, stained using DAPI, 
are shown in blue. This experiment shows that recombinant 9E10 antibodies efficiently detect Myc tags by immunofluores-
cence and that the multi-species strategy can be used to change the species of natural antibodies. Bar = 20 μm.BMC Biotechnology 2009, 9:14 http://www.biomedcentral.com/1472-6750/9/14
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siently expressing Myc-tagged GFP-CLIP-170 [11] (Figure
4). This experiment showed that human and rabbit 9E10
were as efficient as the original mouse 9E10 in their ability
to detect the overexpressed protein.
Discussion
With the increasing power of large-sale projects in genom-
ics, transcriptomics and proteomics and the rise of reverse
genetics, the need for specific antibodies has dramatically
increased [see for example [4,12]]. The recombinant
approach is certainly a powerful alternative to classical,
animal based approaches, in terms of price, speed and
ethics. We and others have demonstrated that a large
diversity of antibodies can be obtained this way (e.g.
against haptens, proteins, glycolipids, particular confor-
mation or post-translational modifications [2]). However,
and despite the identification of high quality recombinant
antibodies, their use is still limited, with very few fee-for
service recombinant antibody companies on the market
and almost no recombinant antibodies in the catalog of
antibody providers. This may be due to the fact that, in
general, the lack of avidity of monomeric recombinant
antibodies strongly limits their sensitivity and that dedi-
cated protocols have to be followed to efficiently use these
antibodies. Different approaches have been developed to
improve recombinant antibody avidity [see [13]]. The
expression system we developed here helps to solve some
of the above cited limitations while bringing unique ver-
satility to recombinant antibodies. It additionally allows
production of endotoxin-free recombinant antibodies.
We have used it so far for more than 12 recombinant anti-
bodies with comparable success (unpublished data). Fur-
thermore, we show that this strategy can be applied not
only to synthetic recombinant antibodies but also to nat-
ural ones. This may be interesting not only for changing
antibody isotype or species but also to save valuable mon-
oclonal antibodies from hybridomas that grow poorly or
do not produce anymore. A limitation of our approach
however is that some natural antibodies cannot be
adapted to the scFv format without a strong loss in affin-
ity.
By fusing scFv to an Fc region, we observed as suggested
before [14,15], that the antibodies keep their specificity
and gain in sensitivity. scFv-xFc can be used like any natu-
ral antibody, without the user actually needing to know
that the antibody is a recombinant one. For general use a
simple, non purified, cell culture supernatant from CHO
cells expressing the antibodies can be diluted between
twenty and a thousand times. Importantly, we believe that
it is more important to estimate recombinant antibodies
"usability" or "effectiveness" instead of their "affinity".
This is what is actually done for natural antibodies where
the user selects the antibody giving the best signal to noise
ratio while the affinity is rarely measured.
A key feature of our strategy is to free the antibody from
its species-specificity restriction with the immediate abil-
ity, in one single sub-cloning step, to fuse the scFv to dif-
ferent Fc regions belonging to various species. The same
antibody and therefore epitope recognized, can thus be
used as a human, mouse or rabbit version. This opens up
previously unattainable multiplexing possibilities since
the antibody species is no longer a factor limiting combi-
nations.
Conclusion
We developed here a comprehensive and integrated sys-
tem for multi-species antibody production. It will sim-
plify and strengthen the use of recombinant antibodies
for daily laboratory applications and permit a flexibility
and choice in multiplexing, previously not feasible. This
simple and fully in vitro system, with no animal use, will
ensure constant and endless production of antibodies
belonging to any species and to any isotype. This may rep-
resent a breakthrough not only for their general labora-
tory use but also for diagnosis where multiplexing and
constant quality are essential.
Methods
Cells and media
HeLa cells were maintained in Dulbecco's Modified Eagle
Medium (DMEM) containing 10% heat-inactivated fetal
calf serum (FCS), 2 mM L-Glutamine.
Chinese hamster ovary (CHO) cells were maintained in
DMEM-F12 containing 10% FCS, 2 mM L-Glutamine.
Strains and plasmids constructions
The construction of scFv 9E10 (anti-Myc tag) has been
described previously [10].
The NotI site (4025) present in the pFUSE-hFc2(IL2ss)
vector (InvivoGen, CA, USA) was mutated by fill-in using
the Klenow enzyme (Biolabs) followed by auto-ligation.
Then a multiple cloning site (MCS) was added between
the IL2ss and the hIgG2Fc by ligating a synthetic adaptor
(5' AATTC GATAT CGGCC ATGGT TTGGT ACCTT GC 3'
and 5' GATCT AGCGG CCGCA AGGTA CCAAA CCATG
GC 3') between EcoRI (626) and BglII(648). The final
construct contains the following MCS : EcoRI-EcoRV-
NcoI-NotI-BglII.
pFUSE-rFc2(IL2ss) and pFUSE-mFc2(IL2ss) vectors were
mutated in their Fc part (respectively IgG and IgG2a) to
remove the NcoI site using a QuikChange site-directed
mutagenesis kit (Stratagene, CA, USA) and the following
primers : for rabbit Fc : forward primer 5' AGCCG AAGGT
CTACA CAATG GGCCC TCCCC GGGA 3' and backward
primer 5' TCCCG GGGAG GGCCC ATTGT GTAGA
CCTTC GGCT 3' ; for mouse Fc : forward primer 5' TGATCBMC Biotechnology 2009, 9:14 http://www.biomedcentral.com/1472-6750/9/14
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TCCCT GAGCC CTATG GTCAC ATGTG TGGT 3' and
backward primer 5' ACCAC ACATG TGACC ATAGG
GCTCA GGGAG ATCA 3'
The Fc fragment of rabbit or mouse vectors were then sub-
cloned into the mutated pFUSE-hFc2(IL2ss) vector using
BglII and NheI. scFvs were then inserted in the modified
vectors between NcoI and NotI. The plasmids were depos-
ited on Genbank under accession numbers FJ716123,
FJ716124 and FJ716125.
Transient transfection
CHO cells were cultivated into 75 cm2  tissue culture
flasks. Twenty four or forty eight hours after, when the
cells reached 90% confluence, transfection was performed
using 20 μg of plasmid DNA and 30 μL of
lipofectamine2000 (Invitrogen, La Jolla, USA) during
4h30 according to the manufacturer's recommendations.
Transfection medium was then removed and cells were
incubated at 30°C with fresh DMEM-F12 for 72–96
hours. Cell supernatants were then harvested and kept at
4°C, or aliquoted and stored at -20°C. Stable cell lines
were also selected for some antibodies. Depending on the
antibody expressed, we obtained between 0.2 and 2 mg of
antibody per Liter of medium. It is likely however that
higher production may be achievable after optimization
[see [16]].
Western Blot
After boiling in SDS-PAGE loading buffer, the samples
were separated on a 12% SDS-PAGE and transferred to
nitrocellulose membranes (Whatman GmbH, Dassel,
Germany). For the experiment presented in Figure 1C, a
loading buffer that did not contain DTT was used. Mem-
branes were blocked in 3% non-fat milk-PBS (Phosphate
Buffer Saline) with 0.2% Tween 20 for 1 h at room tem-
perature or overnight at 4°C. Supernatants of scFv-xFc
were used at 1/300 and added to the membranes for 1 h.
Blots were then washed and incubated 1 h with secondary
anti-human (or anti-mouse or anti-rabbit) HRP labeled
antibodies (diluted at 1/10000 in PBS 0.1% Tween 20)
(Jakson ImmunoResearch Laboratories, Westgrove, PA,
USA). After 5 washes with PBS 0.1% Tween 20, secondary
antibodies were then revealed using the SuperSignal
chemoluminescent reagent (Pierce, Rockford, IL, USA)
and Hyperfilm ECL (GE HealthCare, Velizy, France).
Immunofluorescence
Immunofluorescence labeling were performed on HeLa
cells. Cells were either fixed in 3% paraformaldehyde and
permeabilized with PBS plus 0.1% saponin or fixed and
permeabilized with cold methanol for 4 min at -20°C.
scFv-xFc-containing supernatants were used diluted from
1/20 (anti-Myc) to 1/1000 (anti-Giantin) times and incu-
bated for 1 hr on cells. Cells were then rinsed twice and
incubated with secondary antibodies for 30 min (Jackson
ImmunoResearch Laboratories, Westgrove, PA, USA).
Purified scFv were used as described using short washes
[9].
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